[Renal Involvement in Connective Tissue Diseases]

Area of Science:

• Nephrology
• Rheumatology
• Internal Medicine

Background:

• Renal involvement is a common and heterogeneous complication of connective tissue diseases (CTDs), significantly influencing prognosis and mortality.
• Different CTDs exhibit distinct renal manifestations: proliferative glomerulonephritis in systemic lupus erythematosus (SLE), interstitial nephritis in primary Sjogren's syndrome, and scleroderma renal crisis (SRC) in systemic sclerosis (SSc).

Purpose of the Study:

• To review the spectrum of renal involvement in major CTDs, including systemic lupus erythematosus, primary Sjogren's syndrome, and systemic sclerosis.
• To highlight diagnostic approaches and therapeutic strategies for managing kidney diseases associated with these conditions.

Main Methods:

• Review of literature on renal manifestations in systemic lupus erythematosus, Sjogren's syndrome, and systemic sclerosis.
• Emphasis on diagnostic tools: urine analysis, proteinuria assessment, plasma creatinine, blood pressure monitoring, and kidney biopsy.
• Discussion of treatment modalities, including immunosuppression, alkali therapy, and specific pharmacotherapies like ACE inhibitors.

Main Results:

• Systemic lupus erythematosus commonly presents with proliferative glomerulonephritis, requiring biopsy-guided treatment.
• Primary Sjogren's syndrome predominantly shows interstitial nephritis with tubular dysfunction, managed with immunosuppression.
• Scleroderma renal crisis, a severe complication of systemic sclerosis, is characterized by hypertension and acute kidney injury, with risk factors including diffuse cutaneous involvement and corticosteroid/calcineurin inhibitor use. ACE inhibitors are crucial for management.

Conclusions:

• Regular renal monitoring, including urine and blood tests and blood pressure checks, is essential for patients with CTDs.
• Kidney biopsy is critical for accurate diagnosis, particularly in lupus nephritis and Sjogren's syndrome-related kidney disease.
• Tailored treatment strategies, from immunosuppression to ACE inhibitors, are vital for improving renal outcomes in CTD-associated kidney diseases.